BusinessDermira Reports Third Quarter 2016 Financial Results and Provides Corporate UpdateBy Nasdaq OMXNov 7, 2016, 9:08 PM UTC
BusinessDermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for DermatologistsBy Nasdaq OMXOct 21, 2016, 11:30 AM UTC
BusinessDermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology ConferenceBy Nasdaq OMXOct 13, 2016, 11:31 AM UTC
BusinessCIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque PsoriasisBy Nasdaq OMXOct 3, 2016, 6:00 AM UTC
BusinessDermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology CongressBy Nasdaq OMXOct 1, 2016, 7:05 AM UTC
BusinessDermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from TakedaBy Nasdaq OMXSep 12, 2016, 11:30 AM UTC
